Pablo Gajate - Publications

Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.

Journal: Cancers

Published: June 11, 2026

DNA damage response pathway alterations in urothelial carcinoma: a road to precision oncology or a dead-end street?

Journal: The oncologist

Published: May 11, 2026

Impact of re-transurethral resection of bladder staging on risk stratification of high-grade T1 non-muscle-invasive bladder cancer across European Association of Urology 2021 risk groups.

Journal: BJU international

Published: March 03, 2026

Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.

Journal: International journal of molecular sciences

Published: November 18, 2025

Toxicity Profile of New Therapies in Metastatic Urothelial Carcinoma and Its Impact on Treatment Selection.

Journal: Cancers

Published: September 15, 2025

Clinical and treatment patterns of advanced and radioiodine-refractory differentiated thyroid cancer. ERUDIT study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 01, 2025

Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.

Journal: BJU international

Published: August 29, 2025

Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 03, 2025

New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer.

Journal: Actas urologicas espanolas

Published: January 06, 2025

Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 18, 2024

A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE).

Journal: Clinical genitourinary cancer

Published: September 02, 2024

Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients.

Journal: The oncologist

Published: April 15, 2024